Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205983 · ClinicalTrials.gov registry record · NA
The Effects of Hydromorphone on Responses to Verbal Tasks
A NA study of Healthy, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02205983: Completed NA study of Healthy, sponsored by University of Chicago.
NCT02205983 is a NA study of Healthy that has completed, run by University of Chicago. The registered enrollment target is 50 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02205983, a NA study of Healthy, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will examine the effects of hydromorphone, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opioids and opiates in mediating social behavior in humans and other animals, and particularly, in social distress. The investigators have recently shown that buprenorphine, a partial mu-opioid agonist, reduces cortisol responses to stress. Here, the investigators propose to further explore the role of the opioid system in mediating stress responses in humans through the use of hydromorphone, a full mu opioid agonist, in addition to acetaminophen. The investigators hypothesize that like acetaminophen, hydromorphone will reduce both physiological and subjective measures of stress.
Primary Outcome
The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". The "Feel Drug", "Feel High", "Like Drug", and "Want More" subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the out
Conditions Studied
Interventions
- DRUG 2 mg hydromorphone
- DRUG 1000 mg Acetaminophen
- DRUG 4 mg hydromorphone
- DRUG dextrose
Study Locations (1)
Illinois
- University of Chicago Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT02205983 record still lists
NCT02205983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which 2 mg hydromorphone is the first listed.
NCT02205983 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02205983 about?
NCT02205983 is a clinical study titled "The Effects of Hydromorphone on Responses to Verbal Tasks". In this study, the investigators will examine the effects of hydromorphone, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opio...
What is the current status of trial NCT02205983?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2015-01. Estimated completion is 2016-09.
What conditions does trial NCT02205983 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02205983?
The interventions under investigation include: 2 mg hydromorphone (DRUG), 1000 mg Acetaminophen (DRUG), 4 mg hydromorphone (DRUG), dextrose (DRUG).
Who is sponsoring clinical trial NCT02205983?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02205983 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02205983's enrollment target sits among peer trials
50 448th of 1090 higher than 618 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia